Cerca Biotech — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Cerca Biotech GmbH, founded in 2018 and headquartered in Berlin, Germany, is a commercial-stage diagnostics company specializing in women's health. Its core portfolio includes MammaTyper®, a molecular RT-qPCR test for breast cancer classification, and RNXtract®, a sample preparation product for FFPE tissue. The company is also developing CercaTest RED™, a point-of-care, non-invasive urine test for pre-eclampsia, positioning it at the intersection of precision oncology and rapid obstetric diagnostics. As a subsidiary of China's Shuwen Biotech, Cerca serves as the commercial gateway for these technologies in the European market.

OncologyObstetrics & Gynecology

Technology Platform

Molecular diagnostics platform utilizing RT-qPCR for quantitative mRNA analysis and rapid point-of-care lateral flow technology.

Opportunities

The growing emphasis on precise, molecular-based diagnostics in breast cancer (e.g., for HER2-low) creates a direct opportunity for MammaTyper®.

Furthermore, there is a significant unmet need for rapid, non-invasive point-of-care tests in obstetrics, which CercaTest RED™ aims to address, potentially revolutionizing pre-eclampsia triage.

Risk Factors

Key risks include commercial challenges in displacing entrenched, traditional diagnostic methods like IHC in breast cancer, and intense competition in both the molecular oncology and rapid diagnostic test markets.

Dependency on its parent company, Shuwen Biotech, for technology and strategy also presents an integration and control risk.

Competitive Landscape

In breast cancer diagnostics, Cerca competes with established IHC services, central-lab genomic assays (e.g., Exact Sciences' Oncotype DX, Agendia's MammaPrint), and other molecular subtyping tools. In pre-eclampsia, it will face competition from other companies developing POC biomarker tests (e.g., tests for sFlt-1/PlGF ratio) and traditional clinical assessment methods.

More companies in Diagnostics & Precision Medicine →More companies in Germany →